创新药概念午后躁动，药ETF快速翻红冲击“八连升”！博瑞医药盘中暴拉17%创历史新高

Group 1 - The pharmaceutical sector experienced a sudden surge on July 18, with the drug ETF (562050) quickly turning positive, indicating strong buying interest [1] - The drug ETF (562050) is the first ETF in China tracking the CSI Pharmaceutical Index, focusing on innovative drugs and traditional Chinese medicine, while excluding medical and CXO sectors [1] - As of the report, the component stocks of the drug ETF showed mixed performance, with Borui Pharmaceutical soaring by 17% to reach a historical high, while Sanofi and other companies faced declines [1] Group 2 - According to Dongwu Securities, Borui Pharmaceutical's dual-target GLP-1/GIP receptor agonist BGM0504 has had its IND application accepted [2] - The 11th batch of national drug centralized procurement has been initiated, emphasizing principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and avoiding internal competition" [4] - Goldman Sachs noted that the overall market capitalization of Chinese biotech companies is only 14%-15% of their U.S. counterparts, despite contributing nearly 33% to global innovation, indicating a "value gap" for leading Chinese pharmaceutical companies [4] Group 3 - The drug ETF (562050) offers a comprehensive investment tool covering "chemical drugs, biological drugs, and traditional Chinese medicine," providing high growth driven by innovative drugs while mitigating index volatility through traditional medicine [4] - For those interested in medical devices and CXO, the largest medical ETF in A-shares (512170) is recommended, focusing on "medical devices and medical services" with a high correlation to AI healthcare [4]